CURRENT
ISSUE
1587

The FDA has approved trifarotene 0.005% cream (Aklief – Galderma) for topical treatment of acne vulgaris in patients ≥9 years old. Trifarotene is the fourth topical retinoid to be approved in the US for treatment of acne; tretinoin (Retin-A, and others), adapalene (Differin, and generics), and tazarotene (Tazorac, and others) have been available by prescription for decades. Adapalene 0.1% gel has been available over the counter since 2016 for treatment of acne in patients ≥12 years old.1

TOPICAL RETINOIDS FOR ACNE —...  Continue reading

More from Issue 1587
Previous Issue: 1586      December 2, 2019
Coming Soon
Drugs for Psoriatic Arthritis
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza
Midazolam Nasal Spray (Nayzilam) for Seizure Clusters
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
FROM
ISSUE
1587

Annovera (TherapeuticsMD), a contraceptive vaginal ring that releases segesterone acetate, a synthetic progestin, and ethinyl estradiol, was approved by the FDA in 2018 and is now available. It is the first product to contain segesterone and the second vaginal ring to become available in the US; NuvaRing, which delivers etonogestrel and ethinyl estradiol, was the first.1 Unlike NuvaRing, which requires use of a new ring each month, the Annovera ring can be used for an entire year, but it must be removed for one ... Continue reading